Your browser doesn't support javascript.
loading
Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis.
Haluzík, Martin; Seufert, Jochen; Guja, Cristian; Bonnemaire, Mireille; Bigot, Gregory; Tournay, Mathilde; Kis, János Tibor; Freemantle, Nick.
Afiliación
  • Haluzík M; Institute for Clinical and Experimental Medicine and Charles University, Prague, Czech Republic.
  • Seufert J; Division of Endocrinology and Diabetology, Department of Medicine II, Medical Centre-Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Guja C; Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Bonnemaire M; General Medicines, Sanofi, Paris, France. mireille.bonnemaire@sanofi.com.
  • Bigot G; IVIDATA Group, Paris, France.
  • Tournay M; International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.
  • Kis JT; Department of Internal Medicine Centrum, Szent János Hospital, Budapest, Hungary.
  • Freemantle N; Institute of Clinical Trials and Methodology, University College London, London, UK.
Diabetes Ther ; 14(4): 639-652, 2023 Apr.
Article en En | MEDLINE | ID: mdl-36787044
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies Idioma: En Revista: Diabetes Ther Año: 2023 Tipo del documento: Article País de afiliación: República Checa
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies Idioma: En Revista: Diabetes Ther Año: 2023 Tipo del documento: Article País de afiliación: República Checa